Market Cap 8.74M
Revenue (ttm) 1.50M
Net Income (ttm) -12.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -864.00%
Debt to Equity Ratio 0.00
Volume 51,000
Avg Vol 44,622
Day's Range N/A - N/A
Shares Out 5.83M
Stochastic %K 65%
Beta 1.30
Analysts Strong Sell
Price Target $13.67

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology
Sector: Healthcare
Phone: (215) 948-4119
Website: aprea.com
Address:
3805 Old Easton Road, Doylestown, United States
thedonutman
thedonutman Oct. 3 at 3:48 PM
$APRE I am new here. Bought in yesterday. One question: are they expecting revenue sometime in the near future? Thank you.
0 · Reply
bgurps
bgurps Oct. 3 at 3:16 PM
0 · Reply
AlwaysLearning72
AlwaysLearning72 Oct. 3 at 12:36 PM
$APRE hopefully we get some positive news on their pipeline soon
0 · Reply
AlwaysLearning72
AlwaysLearning72 Sep. 26 at 5:05 PM
$APRE patiently waiting for some positive updates on their pipeline
2 · Reply
BUKUDATBULL
BUKUDATBULL Sep. 26 at 11:00 AM
$APRE $STFS $MRM $ALXO JUST SUM IM MAYBE GOING TO BE IN ✌️🤷‍♂️🤑
0 · Reply
TezBunny
TezBunny Sep. 21 at 9:13 PM
$APRE we can get this under a dollar together
1 · Reply
TezBunny
TezBunny Sep. 20 at 9:27 AM
$APRE let’s get this sucker under a dollar
1 · Reply
FloFloFloFlo
FloFloFloFlo Sep. 17 at 8:11 PM
$APRE is this a zombie biotech company as they call it? Too few staff, no?
1 · Reply
topstockalerts
topstockalerts Sep. 17 at 1:02 PM
Pre Market Top Gainers PT2 $SQFT $CWD $FGNX $APRE $ELOG
0 · Reply
AlwaysLearning72
AlwaysLearning72 Sep. 11 at 1:50 PM
0 · Reply
Latest News on APRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024


Aprea Therapeutics to Present at BIO International Convention

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention


Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

Feb 13, 2023, 7:00 AM EST - 2 years ago

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split


thedonutman
thedonutman Oct. 3 at 3:48 PM
$APRE I am new here. Bought in yesterday. One question: are they expecting revenue sometime in the near future? Thank you.
0 · Reply
bgurps
bgurps Oct. 3 at 3:16 PM
0 · Reply
AlwaysLearning72
AlwaysLearning72 Oct. 3 at 12:36 PM
$APRE hopefully we get some positive news on their pipeline soon
0 · Reply
AlwaysLearning72
AlwaysLearning72 Sep. 26 at 5:05 PM
$APRE patiently waiting for some positive updates on their pipeline
2 · Reply
BUKUDATBULL
BUKUDATBULL Sep. 26 at 11:00 AM
$APRE $STFS $MRM $ALXO JUST SUM IM MAYBE GOING TO BE IN ✌️🤷‍♂️🤑
0 · Reply
TezBunny
TezBunny Sep. 21 at 9:13 PM
$APRE we can get this under a dollar together
1 · Reply
TezBunny
TezBunny Sep. 20 at 9:27 AM
$APRE let’s get this sucker under a dollar
1 · Reply
FloFloFloFlo
FloFloFloFlo Sep. 17 at 8:11 PM
$APRE is this a zombie biotech company as they call it? Too few staff, no?
1 · Reply
topstockalerts
topstockalerts Sep. 17 at 1:02 PM
Pre Market Top Gainers PT2 $SQFT $CWD $FGNX $APRE $ELOG
0 · Reply
AlwaysLearning72
AlwaysLearning72 Sep. 11 at 1:50 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 2:26 PM
$APRE Brilliant piece that captures APRE's situation perfectly. So if you want to update your understanding of APRE or get to know APRE better, this is essential reading. https://beyondspx.com/quote/APRE/aprea-s-oncology-rebirth-betting-on-synthetic-lethality-s-targeted-promise-nasdaq-apre#analysis
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 11:45 PM
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 9:07 PM
$BDSX – Load the Boat & Fasten Your Seatbelt Biodesix is sitting at ~$0.44, but the setup is screaming “explosive move”: analysts average $1.75 (range $1.50–$2.10), implying 300–350% upside. Short interest is high (~3.8M shares; 2.6 days to cover; 18% borrow fee), and float is tight—classic squeeze fuel. Recent intraday surges (up near $0.61) on solid volume hint this isn’t dead money. If ASCO or NGS catalyst hits, once it goes, it goes fast. Keeping an eye on similar small-cap catalysts like $BNTC, $APRE, $SLNO, $IMMX. Not financial advice—just spreading info for momentum-seekers. #BDSX #Biotech #Diagnostics #ShortSqueeze #LoadTheBoat #Stocks #MomentumPlay
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 6:46 PM
🚀 Biodesix (BDSX) Bullish Setup 🚀 Trading near $0.45, BDSX ripped after major holder Jack Schuler bought 3.49M shares ($1.5M), raising his stake to 26%—a strong insider confidence play. Q2 revenue hit $20M (+12% YoY) with 80% margins, guidance reaffirmed at $80–85M. Analysts call it a Strong Buy with PT $1.75 (~300% upside). 📊 Similar small-cap biotech/diagnostic movers: $BNTC, $APRE, $SLNO, $IMMX. #BDSX #Biotech #InsiderBuying #StrongBuy #SmallCap #Diagnostics
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 6:45 PM
🚀 Biodesix (BDSX) Bullish Setup 🚀 Trading near $0.45, BDSX ripped after major holder Jack Schuler bought 3.49M shares ($1.5M), raising his stake to 26%—a strong insider confidence play. Q2 revenue hit $20M (+12% YoY) with 80% margins, guidance reaffirmed at $80–85M. Analysts call it a Strong Buy with PT $1.75 (~300% upside). 📊 Similar small-cap biotech/diagnostic movers: $BNTC, $APRE, $SLNO, $IMMX. #BDSX #Biotech #InsiderBuying #StrongBuy #SmallCap #Diagnostics
0 · Reply
HeyHoser
HeyHoser Aug. 25 at 2:36 PM
$APRE scooped a few at $1.62, done buying for now.
1 · Reply
EntryTamer
EntryTamer Aug. 23 at 5:50 AM
$APRE Aprea Therapeutics is a oncology company with clinical setbacks and pipeline restructuring
0 · Reply
HeyHoser
HeyHoser Aug. 21 at 1:36 PM
$APRE loaded $1.58
1 · Reply
Gbeezy
Gbeezy Aug. 14 at 2:06 PM
$APRE lets go I want $2
2 · Reply
Gbeezy
Gbeezy Aug. 14 at 1:42 PM
$APRE this thing alive?
0 · Reply
HeyHoser
HeyHoser Aug. 13 at 3:21 PM
$APRE Whelm me damnit
0 · Reply
d_risk
d_risk Aug. 13 at 5:59 AM
$APRE - Aprea Therapeutics, Inc. - 10Q - Updated Risk Factors APRE flags major new risks: mounting financial losses, going concern doubts, heavy reliance on clinical trial success and regulatory approvals, patient enrollment and third-party challenges, IP gaps for eprenetapopt, fierce competition, cybersecurity, commercialization and reimbursement hurdles, plus geopolitical and economic pressures. #Biotechnology #CompetitivePressure #FinancialLosses #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/APRE/10-Q/2025-08-12
0 · Reply